In Vitro Antibody Affinity Maturation via AID and Pol η Mutagenesis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for producing monoclonal antibodies are lengthy and costly, requiring animal injection and antigen exposure, necessitating a more efficient alternative for generating high-affinity antibodies.

Innovation Solution

In vitro methods involving phage or phagemid clones are diversified using activation-induced deoxycytidine deaminase (AID) and DNA polymerase eta (Pol η) to induce mutagenesis, followed by transfection and panning against antigens for affinity maturation, allowing for the production of high-affinity monoclonal antibodies without the need for animal-based systems.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If animal injection and antigen exposure methods are used to produce monoclonal antibodies, then high-affinity antibodies can be generated, but the process is lengthy and costly

Engineering Contradiction:

Improveantibody affinityVSAvoidproduction time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent replaces the biological system (animal immune response) with an in vitro molecular system. Instead of injecting animals with antigens to elicit natural antibody production, the invention uses phage display technology combined with in vitro somatic hypermutation mechanisms to generate and select antibodies directly in a laboratory setting, thereby reducing production time while maintaining affinity.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the fundamental parameters of the antibody generation process from in vivo to in vitro conditions. By using phage display libraries and controlling mutation rates through controlled DNA recombination and selection processes, the invention accelerates the time required for antibody production while maintaining the ability to generate high-affinity antibodies through directed evolution principles.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If animal injection and antigen exposure methods are used to produce monoclonal antibodies, then high-affinity antibodies can be generated, but the process is costly

Engineering Contradiction:

Improveantibody affinityVSAvoidproduction cost

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent creates a simplified copy of the natural antibody generation process. Instead of relying on complex animal immune systems, the invention uses phage display to create a manageable library of antibody candidates that can be screened and selected in vitro. This copying of the essential function (antibody generation) without the complex biological system reduces costs while maintaining affinity through controlled selection processes.

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent extracts the essential function of antibody generation from the complex animal immune system. By isolating and using phage display technology, the invention separates the antibody production process from animal biology, enabling cost-effective in vitro generation without requiring expensive animal housing, feeding, and ethical compliance infrastructure.

Inventive Principle:

Principle #2Taking out (Extraction)

3Loss of time

If in vitro methods with phage or phagemid clones are used, then production time is reduced, but the complexity of the method increases

Engineering Contradiction:

Improveproduction timeVSAvoidmethod complexity

Core Design Contradiction:

Loss of timeVSDevice complexity

Solution Approach 1:

The patent segments the antibody generation process into distinct modular steps: phage display library construction, in vitro somatic hypermutation, antigen binding selection, and affinity maturation. This segmentation allows each step to be optimized independently and simplifies the overall process by breaking down what would otherwise be a monolithic complex procedure into manageable, sequential operations that reduce total time while maintaining clarity.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables the rapid generation of high-affinity monoclonal antibodies with specific antigen binding, mimicking natural somatic hypermutation processes in vitro, thereby reducing production time and costs while maintaining antigen specificity.

Implementation Method 1

diversifying the library of phage or phagemid clones by contacting the library of phage or phagemid clones with activation-induced deoxycytidine deaminase (AID)

Methodology Applied

Scientific EffectDeamination:

Implementation Method 2

further diversifying the library of phage or phagemid clones by contacting the library of phage or phagemid clones with DNA polymerase eta (Pol η)

Methodology Applied

Scientific EffectDNA synthesis:

Data Source

PatentUS20230295271A1Methods and compositions for in vitro affinity maturation of monoclonal antibodies

Publication Date: 2023.09.21 UNIV OF SOUTHERN CALIFORNIA

AI summary

Methods and systems are provided to induce hypermutation, produce phage libraries displaying mutagenized immunoglobulin variable regions, and conduct affinity maturation based on the use of activation-induced deoxycytidine deaminase (AID) and a low fidelity DNA polymerase eta (pol η). High affinity monoclonal antibodies or antigen-binding fragments thereof produced by these methods are also demonstrated.